Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 11/20 | 0.44 |
| ▸ | NR3C2 | P08235 | 4/20 | 0.43 |
| ▸ | PGR | P06401 | 3/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | SNCA | P37840 | 1/20 | 0.42 |
| ▸ | ADRB3 | P13945 | 5/20 | 0.42 |
| ▸ | ADRB1 | P08588 | 4/20 | 0.42 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4410025 | 0.83 | NR3C1 (0.43) | NR3C1NR3C2PGRKDRSNCA | |
| SCHEMBL3244098 | 0.72 | HTR1A (0.46) | LMNAHTTKDM4EMAPK1 | |
| SCHEMBL9213064 | 0.69 | HTR3E (0.45) | NR3C1NR3C2PGRADRB1LMNA | |
| SCHEMBL7646617 | 0.68 | KDM4E (0.58) | ADRB1LMNAHTTKDM4EMAPK1 | |
| SCHEMBL3263617 | 0.68 | NR3C1 (0.40) | NR3C1KDRSNCALMNAHTT | |
| SCHEMBL5174062 | 0.67 | HTR6 (0.59) | ADRB1LMNAHTTKDM4EMAPK1 | |
| SCHEMBL3243542 | 0.66 | HRH3 (0.49) | — | |
| SCHEMBL5196668 | 0.66 | DRD2 (0.56) | LMNAHTTKDM4EMAPK1 | |
| SCHEMBL3247538 | 0.66 | HTR2A (0.66) | NR3C1NR3C2PGRADRB1HTT | |
| SCHEMBL23745747 | 0.65 | MC5R (0.56) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101406469-B | Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | LUNDBECK & CO AS H | 2012-06-13 | — | — | CN | disclosed |
| EP-2140864-A2 | Use of GAL3 receptor antagonists for the treatment of depression and / or anxiety and compounds useful in such methods | H.Lundbeck A/S (DK) | 2010-01-06 | — | — | EP | disclosed |
| EP-2140862-A2 | Use of GAL 3 receptor antagonists for the treatment of depression and /or anxiety and compounds useful in such methods | H.Lundbeck A/S (DK) | 2010-01-06 | — | — | EP | disclosed |
| US-20090318504-A1 | Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | BLACKBURN THOMAS P | 2009-12-24 | — | — | US | disclosed |
| CN-101406469-A | Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | LUNDBECK & CO AS H (DK) | 2009-04-15 | — | — | CN | disclosed |
| CN-100446767-C | Use of GAL3 receptor antagonists for the manufacture of a medicament for the treatment of depression and/or anxiety and compounds useful in such a method | SYNAPTIC PHARMA CORP (DK) | 2008-12-31 | — | — | CN | disclosed |
| US-7465750-B2 | Use of GAL3 antagonist for treatment of depression and/or anxiety and compounds useful in such methods | H. LUNDBECK A/S (US) | 2008-12-16 | — | — | US | disclosed |
| US-20070259942-A1 | Use of GAL3 antagonist for treatment of depression and/or anxiety and compounds useful in such methods | BLACKBURN THOMAS P | 2007-11-08 | — | — | US | disclosed |
| US-7220775-B2 | Compound useful for the treatment of neuropathic pain | H. LUNDBECK A/S (DK) | 2007-05-22 | — | — | US | disclosed |
| US-20040127502-A1 | Use of GAL3 antagonist for treatment of depression | SYNAPTIC PHARMACEUTICAL CORPORATION | 2004-07-01 | — | — | US | disclosed |
| US-20040110821-A1 | administering to the subject suffering from affective disorder a 3-IMINO-1,3-DIHYDRO-2H-INDOL-2-ONE derivative | H. LUNDBECK A/S (DK) | 2004-06-10 | — | — | US | disclosed |
| CN-1499970-A | Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | �����յٿ�ҩ������˾ | 2004-05-26 | — | — | CN | disclosed |
| US-20040092570-A1 | GAL3 antagonists for the treatment of neuropathic pain | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2004-05-13 | — | — | US | disclosed |
| US-20030078271-A1 | Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | SYNAPTIC PHARMACEUTICAL CORPORATION | 2003-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318504-A1 | Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | GALR3, GALR2, GALR1 | NR3C1 389/4885NR3C2 824/4885PGR 493/4885 |
| US-20030078271-A1 | Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | GALR3, GALR2, GALR1 | NR3C1 389/4885NR3C2 824/4885PGR 493/4885 |
| US-20040110821-A1 | administering to the subject suffering from affective disorder a 3-IMINO-1,3-DIHYDRO-2H-INDOL-2-ONE derivative | GALR3, GALR2, GALR1 | NR3C1 314/4885NR3C2 479/4885PGR 509/4885 |
| US-20040127502-A1 | Use of GAL3 antagonist for treatment of depression | GALR3, GALR2, GALR1 | NR3C1 449/4885NR3C2 859/4885PGR 473/4885 |
| US-20040092570-A1 | GAL3 antagonists for the treatment of neuropathic pain | GALR3, GALR2, GALR1 | NR3C1 1587/4885NR3C2 2661/4885PGR 1512/4885 |
| US-20070259942-A1 | Use of GAL3 antagonist for treatment of depression and/or anxiety and compounds useful in such methods | GALR3, GALR2, GALR1 | NR3C1 454/4885NR3C2 881/4885PGR 656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.